Data signals Ensartinib: 10 Calculated Market Indicators · Vestango Data Signals DS-2026-06-003 Vestango · Data Signals vestango.com/data-intelligence → Data Signal · DS-2026-06-003 · Calculated Market Indicators Ensartinib ALK+ NSCLC:10 Calculated Market Intelligence Indicators Ten market indicators calculated from the Vestango intelligence corpus — regulatory gap geometry, clinical trial density, publication velocity, HTA coverage, safety signal profile, and companion diagnostic infrastructure. Each number surfaces a structural feature of where this drug stands commercially in June 2026. Data date2026-06-16 Signal IDDS-2026-06-003 INNEnsartinib · ALK+ NSCLC Corpus21,751 scored records SourceVestango Data & Intelligence 10 Calculated Indicators Market Intelligence — Derived Metrics Each indicator below quantifies a specific dimension of the ensartinib commercial landscape as of June 2026 — from the EU regulatory gap and HTA readiness to competitive trial pressure, safety signal density, and ALK diagnostic infrastructure depth. 1EU Regulatory Gap Index 5 : 0 ALK-TKI Comparators Authorised in EU vs Ensartinib 5 ALK-TKI competitors hold active EMA marketing authorisations (crizotinib EU/1/12/793, ceritinib EU/1/15/999, alectinib EU/1/16/1169, brigatinib EU/1/18/1264, lorlatinib EU/1/19/1355). Ensartinib: no EPAR, no EU authorisation as of the data date. The EU competitive field is fully populated with authorised alternatives — ensartinib enters a saturated landscape from a position of regulatory absence. EU-authorised ALK-TKI comparators / Ensartinib EU authorisations = 5 / 0. Source: EMA EC Register, Vestango EMA digest v8. 2FDA–EU Access Gap >18 mo Minimum Time Before EU Patients Can Access Ensartinib FDA Traditional Approval granted 18 December 2024. No EMA marketing authorisation application confirmed in the Vestango corpus as of the data date. Published median FDA-to-EMA authorisation lag for oncology drugs: 12–15 months (Putignano et al., J Pharm Policy Pract, 2022) — applicable only once a parallel filing exists. The EU access gap is currently open-ended and growing with each passing month. FDA approval: 18 Dec 2024. EMA MAA: not confirmed filed. Published oncology FDA→EMA median: 12–15 months (Putignano et al., 2022). 3HTA Coverage Rate 0 / 10 HTA Decisions Initiated or Completed — June 2026 Zero of 10 monitored HTA agencies (NICE, G-BA, HAS, AOTMiT, SMC, AWMSG, ZIN, TLV, NCPE, EUnetHTA) have initiated or completed any assessment for ensartinib. EUnetHTA JCA requires prior EMA marketing authorisation to commence. National HTA assessment is structurally blocked across all 10 monitored markets until EU authorisation is granted. HTA decisions initiated or completed / 10 monitored agencies = 0/10 = 0%. Source: Vestango HTA digest v8. 4Competitive Trial Pressure 10.9× Recruiting Landscape Trials per Direct Ensartinib Trial For every 1 direct ensartinib trial (130 total), there are 10.9 other trials actively recruiting in the broader ALK+ NSCLC landscape (1,415 of 8,909 total). The full corpus ratio is 68.5× (all 8,909 landscape trials vs 130 direct) — but the recruiting subset is the commercially relevant pressure: each recruiting competitor trial is actively enrolling the same patient population. 1,415 recruiting landscape trials / 130 direct ensartinib trials = 10.9×. Full corpus: 8,909 / 130 = 68.5×. Source: Vestango CT digest v9. 5Field Publication Velocity 444 ALK+ NSCLC Landscape Publications Per Year — 2024–2026 1,111 publications indexed from 2024 to mid-2026 across the ALK+ NSCLC field (2.5 years) = 444 per year, or approximately 1.2 per day. Of these, only 44 (4.0%) name ensartinib directly — equivalent to 18 ensartinib-specific publications per year. The field is generating evidence at high velocity; ensartinib’s direct share of that output is limited. 1,111 ALK+ NSCLC pubs 2024+ / 2.5yr = 444/yr. Ensartinib-direct: 44 / 2.5yr = 18/yr. Source: Vestango PubMed digest v3. 6Evidence Base Concentration 2.4% Publications Naming Ensartinib Directly — % of Total Indexed Literature 123 of 5,180 publications name ensartinib, X-396 or eXALT in the title or abstract (2.4%). A broader scoring-based definition (score S≥2.0) yields 481 records — these include network meta-analyses and comparisons where ensartinib is one of multiple arms. An HTA reviewer reading the ALK+ NSCLC literature encounters ensartinib in fewer than 1 in 40 papers in this indication. 123 ensartinib-named / 5,180 total × 100 = 2.4%. Broader scoring definition: 481/5,180 = 9.3%. Source: Vestango PubMed digest v3. 7Safety Signal Density 8.6% Safety-Classified Signals as % of Total Signal Corpus 86 of 1,004 classified signals are safety-related. At 8.6%, this is lower than tarlatamab (14.5% in DS-2026-06-002) — consistent with the different toxicity profile of a small-molecule TKI versus a bispecific T-cell engager. ALK inhibitors carry known class effects: interstitial lung disease, hepatotoxicity, CNS toxicity — 86 signals indicate active pharmacovigilance requirements across any future HTA submission. 86 safety signals / 1,004 total signals × 100 = 8.6%. Source: Vestango signals digest v4, by_signal_type field. 8CDx Infrastructure Readiness 9 / 10 ALK CDx Records Confirmed — FDA + EU Combined 9 of 10 CDx records in the Vestango registry are ALK-confirmed (8 FDA, 1 EU IVDR). Three validated platforms available: Ventana ALK (D5F3) IHC, Vysis ALK Break Apart FISH, FoundationOne CDx NGS. The diagnostic infrastructure for patient selection pre-exists and is mature. This is a TYPE 2 gap — the bottleneck is HTA evidence and EU authorisation, not diagnostic availability. 9 ALK-confirmed CDx records / 10 total CDx records screened = 90%. FDA: 8 records. EU IVDR: 1 record. Source: Vestango CDx digest v3. 9Pipeline Signal Dominance 45.7% Pipeline-Classified Signals as % of Total Signal Corpus 459 of 1,004 signals are classified as pipeline — the single largest category. Regulatory signals account for only 1.2% (12 signals); reimbursement for 1.7% (17 signals). The signal distribution reveals a compound still in the clinical development phase of its commercial lifecycle despite US approval: EU regulatory and reimbursement signals remain structurally absent from the corpus. 459 pipeline / 1,004 total = 45.7%. Regulatory: 12/1,004 = 1.2%. Reimbursement: 17/1,004 = 1.7%. Source: Vestango signals digest v4. 10Evidence Curation Ratio 1.1% Top-Evidence Records as % of Total Scored Corpus Only ~249 of 21,751 scored records (1.1%) passed the top-evidence threshold (score ≥30) across all data layers — 236 from PubMed, 13 from ClinicalTrials. Each retained record represents a verified, high-relevance data point. The 98.9% excluded constitutes the filtering depth behind each finding in the full intelligence package. ~249 score-≥30 records (PubMed: 236, CT: 13) / 21,751 total scored × 100 ≈ 1.1%. Source: Vestango aggregate v5. Visual Summary Signal Distribution — Where the Evidence Pressure Sits Distribution of 1,004 classified market signals by type — revealing the structural imbalance between pipeline activity and regulatory or reimbursement signal presence. Signal Type Distribution — Ensartinib · 1,004 Classified Signals Vestango Data & Intelligence · DS-2026-06-003 · Data date: 2026-06-16 Ensartinib signal data: Vestango Ensartinib Regulatory & Market Decision Intelligence Package, DS-2026-06-003. Signal types: pipeline (459), general (237), scientific (193), safety (86), reimbursement (17), regulatory (12). Pipeline dominance (45.7%) alongside near-absence of regulatory (1.2%) and reimbursement (1.7%) signals characterises a compound commercially active in the US but pre-authorisation in the EU. Composite Intelligence Interpretation The 10 indicators collectively describe a compound caught in a structural access asymmetry: mature diagnostic infrastructure (indicator 8: 9/10 ALK CDx confirmed), a real but limited direct evidence base (indicator 6: 2.4% — 1 in 40 field publications), and an active pipeline (indicator 9: 45.7% pipeline signals) — set against a regulatory and reimbursement position of complete absence in Europe (indicators 1, 2, 3: 5 authorised competitors, no confirmed EMA MAA, 0 HTA decisions across 10 agencies). The ALK+ NSCLC field itself is generating 444 publications per year (indicator 5) — the majority documenting competing agents. The competitive recruiting pressure ratio of 10.9× (indicator 4) reflects a saturated clinical space where each delayed year of EU authorisation compounds the evidence disadvantage. The signal corpus confirms the diagnosis: pipeline running, regulatory gateway closed. Source: Vestango Life Sciences · Data & Intelligence · vestango.com/data-intelligence · Signal ID: DS-2026-06-003 · Data date: 2026-06-16 · © 2026 Vestango Life Sciences Sp. z o.o. All rights reserved. · For citation: Vestango Data Signals, DS-2026-06-003 (2026-06-16) Full Intelligence Package — Ensartinib 21,751-record scored corpus · 10 data domains · FDA approval, EMA gap analysis, HTA landscape (10 agencies), ALK CDx registry, clinical trial density, 1,004 classified market signals, and full regulatory timeline documentation. View Package → Tarlatamab: 10 Calculated Market Indicators · Vestango Data Signals DS-2026-06-002v4 Vestango · Data Signals vestango.com/data-intelligence → Data Signal · DS-2026-06-002v4 · Calculated Market Indicators Tarlatamab ES-SCLC:10 Calculated Market Intelligence Indicators Ten market indicators calculated from the Vestango intelligence corpus — regulatory timelines, clinical trial density, publication velocity, HTA coverage, safety signal burden, and CDx infrastructure readiness. Each number tells a different story about where this drug stands commercially in June 2026. Data date2026-06-07 Signal IDDS-2026-06-002v4 INNTarlatamab · ES-SCLC Corpus25,429 scored records SourceVestango Data & Intelligence 10 Calculated Indicators Market Intelligence — Derived Metrics Each indicator below quantifies a specific dimension of the tarlatamab commercial landscape as of June 2026 — from regulatory speed and HTA coverage to competitive trial pressure and diagnostic infrastructure readiness. 1Regulatory Speed 54% Faster than Industry Median — BTD to Traditional Approval Tarlatamab achieved Traditional FDA Approval in 25 months from Breakthrough Therapy Designation (Oct 2023 → Nov 2025). Industry median for BTD-to-approval in oncology: 54 months (FDA CDER BTD Program Annual Report 2023). Tarlatamab approval timeline is 54% shorter. Vestango corpus: 25 months. Benchmark: FDA CDER, Breakthrough Therapy Designation Program: 2023 Annual Report, median oncology BTD-to-approval = 54 months. 2Accelerated Approval Conversion 18 mo Accelerated → Traditional Approval Conversion Speed Tarlatamab converted Accelerated Approval (May 2024) to Traditional Approval (Nov 2025) in 18 months — versus typical oncology AA conversion of 36 months (FDA AA Program Annual Report 2023). Twice as fast as the standard pathway. Vestango corpus: Nov 2025 − May 2024 = 18 months. Benchmark: FDA Accelerated Approval Program Annual Report 2023, median oncology AA-to-full-approval = 36 months. 3Regulatory Speed — FDA to EMA 4 mo FDA–EMA Regulatory Lag — Confirmed (Nov 2025 → Mar 2026) EMA Marketing Authorisation granted 26 March 2026 — only 4 months after FDA Traditional Approval (Nov 2025). Published FDA→EMA median lag for oncology BT drugs: 12–15 months (Putignano et al., J Pharm Policy Pract, 2022). Tarlatamab EU authorisation was 3× faster than the published median. EU number: EU/1/26/2033. Vestango corpus: EMA authorisation 26 Mar 2026 − FDA approval Nov 2025 = 4 months. EU number: EU/1/26/2033. Benchmark: Putignano et al. (2022), EMA-FDA parallel procedures, median EU/US lag 12–15 months, J Pharm Policy Pract. 4HTA Coverage Gap 0 / 10 Positive HTA Reimbursement Decisions — June 2026 Zero of 10 monitored HTA agencies have issued a positive reimbursement recommendation. NICE rejected (Jul 2025). EUnetHTA JCA ongoing. 8 agencies: no decision on record. Despite US approval, positive HTA coverage = 0%. Positive decisions / Total agencies monitored = 0/10 = 0% 5Competitive Pressure Index 31.4× Landscape Trials per Direct Tarlatamab Trial (Recruiting) For every 1 direct tarlatamab trial (50 total), there are 31.4 other trials actively recruiting in the SCLC/DLL3 landscape (1,570 recruiting). Indicates substantial competitive clinical activity in the same therapeutic space. 1,570 recruiting trials / 50 direct tarlatamab trials = 31.4× 6Scientific Momentum 827 New Publications Per Year — 2024–2026 Annualised Rate 2,068 publications indexed from 2024 to mid-2026 (2.5 years) = 827 per year annualised — equivalent to 2.3 new publications per day. Indicates sustained and intensifying scientific engagement. 2,068 publications / 2.5 years = 827/yr = 2.3/day 7Safety Signal Density 14.5% Safety-Classified Signals as % of Total Signal Corpus 35 of 241 classified signals are safety-related (ICANS, CRS, interstitial lung disease). At 14.5%, this exceeds the typical oncology safety signal density for approved immunotherapies, indicating active pharmacovigilance requirements across all HTA submissions. 35 safety signals / 241 total signals × 100 = 14.5% 8CDx Infrastructure Gap 0% DLL3 CDx Coverage — EU Certified Manufacturer Screen 310 EU-certified medical device manufacturers screened against EUDAMED IVDR registry. DLL3-targeting companion diagnostic coverage: 0 of 310 manufacturers. No FDA-approved DLL3 CDx either. Global CDx infrastructure for patient selection = absent. DLL3 CDx approvals / 310 EU-certified manufacturers screened = 0/310 = 0% 9Literature Recency Index 23.6% Share of Total Literature Published in Last 2.5 Years 2,068 of 8,781 indexed publications appeared in 2024–mid-2026. At 23.6% recency share for a 2.5-year window, tarlatamab generates roughly 3× more annual literature than the historical baseline — a marker of high scientific and commercial priority. 2,068 recent pubs / 8,781 total × 100 = 23.6% in 2.5 years 10Evidence Curation Ratio 3.6% Top-Evidence Records as % of Total Scored Corpus Only 907 of 25,429 scored records (3.6%) passed the top-evidence threshold for inclusion in the curated intelligence layer. Each curated record carries an average of 1.6 verified source links. The 96.4% excluded provides the filtering depth behind each finding. 907 curated / 25,429 scored × 100 = 3.6% · avg 1,440/907 = 1.6 links/record Visual Summary Regulatory Timeline vs Industry Benchmarks Comparison of key tarlatamab milestones with the oncology median for Breakthrough Therapy-designated drugs. Regulatory Milestones — Months from Breakthrough Therapy Designation Tarlatamab vs industry median · Source: Vestango Data & Intelligence · DS-2026-06-002v4 Tarlatamab data: Vestango Tarlatamab Regulatory & Market Decision Intelligence Package, DS-2026-06-002v4 (BTD: Oct 2023, AA: May 2024, Traditional Approval: Nov 2025). Industry medians: (1,2) FDA CDER Breakthrough Therapy Designation Program Annual Report 2023; FDA Accelerated Approval Program Annual Report 2023. (3) Putignano et al., J Pharm Policy Pract, 2022 — EMA/FDA approval lag, median 12–15 months. External benchmarks are not part of the Vestango corpus and are cited independently. Composite Intelligence Interpretation The 10 indicators collectively describe a compound market paradox: exceptional regulatory speed (indicators 1–2) has outpaced HTA and diagnostic infrastructure readiness (indicators 4, 7–8). Tarlatamab achieved FDA approval 54% faster than the oncology median and EU authorisation only 4 months after FDA (vs. 12–15 month median), yet holds zero positive reimbursement decisions across 10 monitored markets and zero approved companion diagnostics globally. Simultaneously, the 31.4× competitive trial density (indicator 5) and 827 annual publications (indicator 6) signal that the scientific and commercial ecosystem around this target is intensifying — creating a window where intelligence on regulatory, HTA and CDx developments carries disproportionate decision value. Source: Vestango Life Sciences · Data & Intelligence · vestango.com/data-intelligence · Signal ID: DS-2026-06-002v4 · Data date: 2026-06-07 · © 2026 Vestango Life Sciences Sp. z o.o. All rights reserved. · For citation: Vestango Data Signals, DS-2026-06-002v4 (2026-06-07) Full Intelligence Package — Tarlatamab 25,429-record scored corpus · 907 curated records · 1,440 source links · 12 modules including full regulatory timeline, HTA evidence requirements, clinical trial landscape, CDx registry cross-reference, and 241 classified market signals. View Package →
